There are many resources supporting pharmacogenomics in pharmacy practice, including articles, books, websites, programs, etc. One must be selective in determining which resources to use so one does not get overwhelmed. The list below is primarily for getting into the field and to serve as resources.

GENERAL

• PHARMgkb The Pharmacogenomics Knowledgebase
  https://www.pharmgkb.org/
  
  
• Genetics Home Reference - Your Guide to Understanding Genetic Conditions
  https://ghr.nlm.nih.gov/primer/genomicresearch/pharmacogenomics

TRAINING PROGRAMS

• UNC Pharmacogenomics 101: What pharmacists need to know to lead the genomics revolution.
  http://www.softconference.com/llc/player.asp?PVQ=HEDL&fVQ=FIHDHH
  
  
• RxGenomix Training Program in Pharmacogenomics
  http://portal.rxgenomix.com/dashboard.php

FDA RESOURCES

• Table of Pharmacogenomic Biomarkers in Drug Labeling
  https://www.fda.gov/drugs/scienceresearch/researchareas/
  pharmacogenetics/ucm083378.htm
  
  
• FDA Drug Label Information
  https://www.fda.gov/drugs/scienceresearch/researchaeas/
  pharmacogenetics/ucm083378.htm
  
  
• GTR: Genetic Testing Registry
  https://www.ncbi.nlm.nih.gov/gtr/

BOOKS

• Kisor DF, Kane MD, Talbot JN et al. Pharmacogenetics, Kinetics, and Dynamics for Personalized Medicine. Burlington, MA: Jones & Bartlett Learning; 2014.

OTHER

• GeneTests, a medical genetics information resource
  https://www.genetests.org/
  
  
• NextGxDx/Concert Genetics
  https://www.concertgenetics.com/
  
  
• Clinical Trials.gov - Trials involving pharmacogenomics or pharmacogenetics
  https://clinicaltrials.gov/search/term=pharmacogenomics+OR
  +pharmacogenetics

News

H.R. 244 Funding Law Includes Compounding Language
The President has signed into law H.R. 244, which provides fiscal year 2017 full-year appropriations through September 30, 2017. It includes bipartisan congressional legislation that clarifies congressional intent on several compounding regulations implementing the Drug Quality and Security Act (DQSA) of 2013. The law instructs FDA to draft new guidances in areas where the agency had misinterpreted the intentions of Congress.

Specifically, the language calls on the FDA to do the following:

1. Draft a new memorandum of understanding (MOU) that allows pharmacies that meet all other requirements of 503A to "distribute" compounded products over state lines.
   
   
2. Draft new Guidance to allow pharmacists to compound for "office use" in anticipation of receiving patient-specific prescriptions at a later time.
   
   
3. Acknowledge that pharmacies compounding under 503A are the purview of state boards of pharmacy and are not to be held to Current Good Manufacturing Practices (CGMPs).

IJPC Now on Facebook and Youtube

Become a fan of the IJPC Facebook page and share ideas, photos, and keep up to date with the latest compounding information - http://www.facebook.com/IJPCompounding

Learn about the Journal's new multi-media features and view our growing collection of educational and training videos at www.ijpc.com/video or by subscribing to our Youtube channel at https://www.youtube.com/user/IJPCompounding.

Did You Know ...

�that the shortest distance between two points is riding with a good friend?

Tip of the Week

We make a living by what we get; we make a life by what we give.

Looking Back

Makes good,
Because it's
Made good!
     Burma Shave